Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: CEOP regimen
Drug: CHOP regimen

First Posted Date: 2009-03-03

Last Posted Date: 2014-08-20

Lead Sponsor: Fudan University

Target Recruit Count: 398

Registration Number: NCT00854568

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: L-asparaginase

First Posted Date: 2009-03-03

Last Posted Date: 2012-02-20

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT00854425

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Radiation Dose Escalation Study for Advanced Liver Cancer

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: 3DCRT/IMRT

First Posted Date: 2009-02-20

Last Posted Date: 2009-02-20

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT00848094

Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer

Phase 1

Conditions: Local Advanced Non-Small Cell Lung Cancer

Interventions: Other: Concurrent Pemetrexed, Cisplatin and Radiotherapy

First Posted Date: 2009-02-18

Last Posted Date: 2009-02-18

Lead Sponsor: Fudan University

Target Recruit Count: 12

Registration Number: NCT00846443

Locations: 🇨🇳
Department of Radiation Oncolory, Cancer Hospital, Fudan University, Shanghai, Shanghai, China

Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)

Phase 2

Conditions: T-Cell Lymphomas
Chemotherapy

Interventions: Drug: FAD

First Posted Date: 2009-02-10

Last Posted Date: 2010-09-15

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT00840385

Locations: 🇨🇳
Cancer Hospital, Fudan University, Shanghai, Shanghai, China

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Phase 2

Conditions: Colorectal Neoplasms

Interventions: Drug: sorafenib
Drug: FOLFIRI

First Posted Date: 2009-02-09

Last Posted Date: 2010-09-15

Lead Sponsor: Fudan University

Target Recruit Count: 43

Registration Number: NCT00839111

Locations: 🇨🇳
Cancer Hospital,Fudan University, Shanghai, Shanghai, China

The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma

Not Applicable

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: interferon-alpha

First Posted Date: 2009-02-09

Last Posted Date: 2012-08-23

Lead Sponsor: Fudan University

Registration Number: NCT00838968

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: docetaxel, cisplatin, fluorouracil
Radiation: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)

First Posted Date: 2009-01-06

Last Posted Date: 2009-01-27

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT00817583

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Fudan University, Shanghai, Shanghai, China

Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: cisplatin
Radiation: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)

First Posted Date: 2009-01-06

Last Posted Date: 2009-01-06

Lead Sponsor: Fudan University

Target Recruit Count: 37

Registration Number: NCT00817258

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Fudan University, Shanghai, China

Effectiveness and Safety of Angongniuhuang Pill on Restoring Consciousness for Patients Who Have Suffered From a Stroke

Phase 2

Conditions: Stroke
Acute Ischemic Stroke

Interventions: Drug: Angongniuhuang Pill
Drug: placebo

First Posted Date: 2009-01-06

Last Posted Date: 2010-05-28

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT00817609

Locations: 🇨🇳
Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy